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ABSTRACT
Fatty acids (FAs) can be classified into saturated (SFA), unsaturated (poly- or 
monounsaturated) and trans FA. Recent studies have found that both the quantity 
and quality of dietary FAs may influence their role in metabolic pathways. Due to their 
chemical composition, some FAs play a major role in the development and progression 
of cardiovascular disease. This is especially true for SFA and n-3 polyunsaturated 
fatty acids, which include marine eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA). The proinflammatory effects of high SFA intake may increase the risk 
of atherosclerosis. On the other hand, dietary n-3 intake may reduce the risk of 
cardiovascular disease by decreasing atherosclerosis, inflammation, and thrombotic 
processes. The goal of this study was to review the current literature on the role of FA 
intake in the prevention and risk of cardiovascular disease.
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ARTICLE SUMMARY
Strengths: The few studies linking diet and the consumption of fatty acids 
to cardiovascular disease increase the strength of this research. Limitations 
of this study: Literature review study with cross-sectional design.
INTRODUCTION
Lipids are a type of macronutrient that, like carbohydrates and proteins, are 
obtained from dietary sources. They are crucial to cell membrane structure 
(phospholipids, sphingolipids, and cholesterol) and metabolic processes 
such as the transportation and absorption of lipid-soluble vitamins (A, D, E 
and K), in addition to playing a role as precursors of hormone synthesis and 
components of bile1. Lipids stored in the form of fat are also responsible for 
body temperature control, organ protection, and energy storage2.
The optimal consumption of lipids, especially fatty acids (FAs), “as a 
percentage of total fat intake in both healthy and sick individuals” is still a 
relevant and debated issue in the development of nutritional recommendations 
by doctors and dietitians3. The goal of this article was to review the role of 
dietary FAs in the development and prevention of cardiovascular disease (CVD).
Fatty Acids
FAs are lipids formed by carbon chains attached to hydrogen atoms with 
an acidic group at one end3. They are classified according to the number 
of double bonds (unsaturations) in their structure. Saturated FAs (SFAs) 
have no double bonds and are mostly obtained from animal fat, such as 
that found in red meat and dairy products3. The major SFAs are lauric, 
palmitic and stearic acids. Unsaturated FAs (UFAs), on the other hand, 
can be divided into monounsaturated (MUFAs) and polyunsaturated FAs 
(PUFAs). The former category contains acids with a single unsaturation, 
the most popular of which is omega 9 (oleic acid). They can be found in 
oils extracted from sources such as olives, avocados, nuts, and almonds4. 
PUFAs, on the other hand, have two or more unsaturations, and are most 
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commonly exemplified by omega-3 and-6 (n-3 and 
n-6)1. The term “omega” refers to the position of the 
first double bound starting from the terminal methyl 
group of the FA molecule5. The main dietary sources 
of PUFAs are canola oil, cold water fish, and some 
seeds (n-3), as well as soy oil (n-6)1.
Unsaturated FAs also include trans FAs (TFAs), 
which are geometric isomers of naturally occurring 
acids, or cis-unsaturated FAs. They are similar to the 
latter in their molecular shape, but differ in terms of 
their molecular structure6. TFAs are naturally produced 
by ruminants through the partial hydrogenation and/or 
isomerization of cis-UFA from the hydrogen released 
during the oxidation process, catalyzed by bacterial 
enzymes7. Artificial trans fats, on the other hand, result 
from the partial hydrogenation of vegetable oils using 
hydrogen gas and a metallic catalyst8. Approximately 
90% of dietary TFAs come from polyunsaturated 
vegetable oils produced by industrial hydrogenation, 
a process in which a hydrogen molecule is added 
as a catalyst to the double bond between carbon 
molecules9. This process decreases unsaturation, 
increases melting points, and improves oxidative 
stability and the functionality of semi-solid fractions, 
and has therefore become widely used in the food 
industry9. The addition of TFAs to processed foods 
improves their flavor, texture and shelf-life10. TFAs can 
be found in products such as cookies, salty snacks, 
pastries, microwave popcorn, biscuits, and most 
foods containing margarine7.
PUFAs include essential acids (EPUFAs), which 
cannot be synthesized by the human body and 
must therefore be obtained from dietary sources. 
Examples of EPUFAs include linoleic (n-6) and 
alpha-linolenic (n-3) acids11. FAs in the n-6 and 
n-3 families, also known as omega-6 and omega-3 
acids, can be obtained from the diet or produced in 
the body from linolenic and alpha-linolenic acids by 
elongase and desaturase activity12. Long-chain n-3 
acids, including those in the EPA (eicosapentaenoic 
acid) and DHA (docosahexaenoic acid) families, 
come mostly from cold water fish and seeds such 
as linseed and chia, and have been found to be 
associated with several health benefits13. They play 
an important role in anti-inflammatory processes, 
membrane viscosity, and general immunity14. DHA 
is present in all tissue membranes and is found in 
abundance in the brain and the retina. EPA and 
DHA are also the precursors of several metabolites 
and important lipid mediators whose widely studied 
health benefits13,14 will be described below. Table 1 
summarizes the names and chemical structure of 
different types of major FAs. Table 2 describes 
the main dietary sources of FAs with the aim of 
facilitating their inclusion in diet plans.
Table 1: Dietary sources of fatty acids.
Type Dietary Source
Saturated fatty acid Whole milk, butter, cream, high-fat cheese (provolone, Parmesan, mozzarella), lard, 
bacon, high-fat meats, poultry and fish skins, coconut milk.
Monounsaturated fatty acid Olive oil, canola oil, olives, avocados, peanuts, chestnuts, walnuts, and almonds.
Polyunsaturated fatty acid Fish, vegetable oils (sunflower, soy, corn, canola, saffron, cotton, sesame) and seeds 
of oleaginous plants (chestnuts, walnuts, hazelnuts).
o Omega-6 Meats, sunflower and primrose oil, pumpkin seeds, corn, hemp, soy, sesame, borage, 
canola, linseed, black gooseberry, and olive oil.
o Omega-3 Fish oil (salmon, tuna, herring, sardines), linseed, chia, hemp, pumpkin seeds, black 
gooseberry, egg yolks, canola oil, and soy oil.
Trans Fatty Acids Ice cream, chocolate, filled rolls, salad dressings, creamy desserts, cookies, chicken 
nuggets, croissants, pies, processed cake, hard margarine, and some fast-food.
Table 2: Recommended fat intake for the prevention of 
chronic disease.
Fatty Acids % TEI
Total 20 to 35%
Saturated <10%
Polyunsaturated 6 to 11%
• Omega-6 2.5 to 9%%
• Omega-3 (EPA and DHA) 0.5 to 2%
• Omega-3 (ALA) >0.5%
Monounsaturated Difference value*
Trans <1%
*Recommended levels of monounsaturated fatty acid intake were 
calculated as follows: total fat - (saturated + polyunsaturated + 
trans fatty acids) TEI - Total energy intake. Source: WHO/FAO15.
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Saturated Fatty Acids and Cardiovascular Risk
Studies performed in the 1980s and 1990s reported 
that the intake of saturated fats and cholesterol is 
associated with the presence of coronary artery disease 
(CAD)16,17. One of the possible mechanisms underlying 
the association between SFA intake and an increased 
risk of CAD is the heightened proinflammatory activity, 
activation of monocytes and macrophages, and the 
release of inflammatory markers from adipocytes18. 
However, recent epidemiological studies19-21 have 
reported varying degrees of association between 
these concepts, ranging from a positive association 
to no discernible relationship20 between dietary 
saturated fats and CAD-related morbidity or mortality. 
It is possible that the effects of dietary SFAs on the 
risk factors for CAD differ depending on the acid in 
question and on its dietary source. For instance, a 
diet high in stearic acid (C18;0) is more effective in 
reducing LDL cholesterol (LDL-c) levels than a diet 
enriched with palmitic acid (C16;0) or with myristic 
(C14;0) and lauric acids (C12;0)22,23. Although all of 
these are SFAs, palmitic acid has a stronger effect 
on increasing LDL-c levels than lauric acid24.
A recent meta-analysis of prospective cohort 
studies of the association between saturated fats and 
cardiovascular disease (CVD) found no significant 
evidence of a relationship between dietary saturated fat 
and a greater risk of CAD25. The study in question also 
suggested that the beneficial effects of low-saturated 
fat diets on CAD risk might be explained by the 
high levels of polyunsaturated fats in these diets25 
rather than by the reduction in saturated fats per se. 
However, a recent evaluation of the data obtained 
from the Sydney Diet-Heart Study revealed that 
the substitution of dietary saturated fats by linoleic 
(n-6) acid (a PUFA) did not lead to any benefits or 
reductions in overall or CAD-related mortality26.
This study also evaluated the relationship between 
dietary FAs and cerebrovascular disease. A recent 
case-control study of 297 patients with a history of 
stroke found that MUFAs, PUFAs, and SFAs play 
independent protective roles against cerebrovascular 
disease, while increased TFA intake leads to an 
increase in the risk of stroke27. These findings are 
similar to those of previous investigations, such 
as the Framingham Heart Study28, which found an 
inverse association between SFA and stroke risk, as 
did the Honolulu Heart Program29. In both studies, 
total lipid intake proved to be negatively associated 
with the incidence of stroke but positively associated 
with coronary disease. Some authors suggest that 
SFAs may have an effect on atherosclerosis in the 
coronary arteries but not on cerebral arteries, since 
the physiopathological mechanisms responsible for 
atherosclerosis may differ between these vessels and 
therefore be differently affected by lipid intake27,30,31.
The latest Cochrane review of the effects of 
saturated fats on cardiovascular outcomes suggested 
that a decrease in SFA intake due to reduced total 
lipid intake or changes in dietary lipid composition 
could reduce the risk of CVD by 14%, according to 
the results of 6-month clinical trials32.
Monounsaturated Fatty Acids and the 
prevention of Cardiovascular Disease
One of the first prospective studies of the effects 
of MUFAs was the Lyon Diet Heart Study, which 
evaluated the beneficial effects of a Mediterranean 
diet in subjects with acute myocardial infarction. 
This study included patients under 70 years of age 
who survived acute myocardial infarction. They were 
assigned either to the intervention group (n = 289), 
which received guidance on the Mediterranean diet 
according to nutritional guidelines, including being 
advised to increase the consumption of fruits, fish 
and olive oil, and a control group (n = 295). Authors 
showed that the Mediterranean diet group had lower 
incidence of mortality and improved lipid profile33. 
There have been several recent meta-analyses34-36 
of cohort studies investigating the effects of dietary 
fat intake on coronary events and cardiovascular 
death. Skeaff and Miller34 did not observe any effect 
of high-MUFA diets on the risk of coronary events or 
death. Jakobsen et al.35 performed a meta-analysis 
of cohort studies involving 344,696 individuals and 
found MUFA-rich diets to be positively associated 
with a risk of coronary events but not with mortality. 
The authors stated that, in Western diets, MUFAs 
are predominantly obtained from animal products, 
which may confound the results of comparisons 
between dietary fat levels35, since the most common 
dietary sources of MUFAs are vegetable products 
containing oleic acid.
Another meta-analysis of cohort studies found 
a significant association between MUFA intake and 
reduced risk of coronary disease36. Two additional 
meta-analyses of randomized clinical trials and 
cohort studies also reported the beneficial effects of 
MUFA-rich diets on the reduction of CVD, although 
these findings were not conclusive37,38.
Polyunsaturated Fatty Acids and the 
Prevention of Cardiovascular Disease
Studies suggest that the consumption of n-3 
PUFAs (EPA and DHA) extracted from fish oils could 
reduce the risk of CVD by decreasing atherosclerosis, 
inflammation, and thrombotic processes39. The benefits 
of n-3 PUFAs in reducing CVD mortality have been 
documented in patients who survived acute myocardial 
infarction14.
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A meta-analysis of randomized studies of patients 
with heart disease showed that dietary supplementation 
with up to 2g/day n-3 EPA and DHA from fish oils 
reduced CAD-related deaths by over 20% but had 
no effect on the occurrence of arrhythmia or death 
from other causes40. Based on another meta-analysis 
of cohort studies and clinical trials, Mozaffarian and 
Rimm concluded that a daily intake of 250mg EPA 
and DHA from natural dietary sources reduced the 
risk of fatal heart disease by 36%, with no additional 
benefit at higher doses41. On the other hand, two 
randomized, placebo-controlled trials of the effects 
of enriched margarine or supplementation with 
1g n-3 FAs (EPA and DHA) in patients with previous 
cardiovascular events or with high cardiovascular 
risk but no actual history of heart disease found 
that supplementation with n-3 FAs did not lead to 
a significant reduction in cardiovascular events or 
mortality risk in these subjects40,42.
There is still limited evidence of the protective 
effects of plant-derived alpha-linolenic acid (ALA). 
A meta-analysis of five prospective studies showed 
that the risk of fatal CAD was 21% lower in individuals 
with high ALA intake (up to 2.0g/day) than in those 
who consumed less than 1.2g ALA/day, with both 
groups obtaining this FA from dietary vegetable 
oils43. In the Nurses’ Health Study, which involved a 
cohort of 76,763 women with no history of cancer or 
CVD, ALA intake was investigated using a nutritional 
questionnaire, administered at the beginning of the 
study in 1984 and throughout an 18-year follow-up. 
The study found that increased ALA intake might 
decrease the risk of CVD44.
Studies of dietary n-3 levels have found that these 
compounds reduce vulnerability to arrhythmia by 
stabilizing the myocardial membrane45,46. These findings 
corroborate the inverse relationship between the dietary 
intake of EPA and DHA from fish and the risk of sudden 
heart-related death reported in both case-control 
and cohort studies47,48. Erkkilä et al.48 randomized 
33 subjects with CVD into one of three groups with 
varying levels of n-3 intake: an increased lean fish 
intake group, an increased fatty fish consumption 
group, or a control group. These diets were followed 
for a period of eight weeks. The group who ate fatty 
fish four times a week (approximately 1.07g/day 
n-3) showed a significant increase HDL cholesterol 
(HDL-c) in 62mg/dL relative to the control group, 
suggesting a beneficial health effect of fish oil PUFAs 
(48). The dose-response relationship between EPA 
and DHA intake and the risk of cardiac death has 
not been well established. However, some authors 
hypothesize that the variability of findings on the topic 
may be associated with the different ethnic features 
of the populations examined by each study49.
A meta-analysis of randomized controlled trials 
that evaluated the effects of n-6 acids and of the 
combination of n-6 and n-3 acids criticized studies 
which suggest that dietary SFAs be replaced with 
vegetable oil omega-6 acids. The article also points 
out several limitations of previous meta-analyses 
on the topic, such as the omission of relevant trials 
with unfavorable outcomes, the inclusion of studies 
with weak design and several confounders, and a 
failure to distinguish between trials that selectively 
increased n-6 intake from those that focused on n-3 
PUFA intake only50.
Trans Fatty Acids and Cardiovascular Disease
The negative health effects of TFAs obtained from 
industrially produced partially hydrogenated vegetable 
oils have been demonstrated by several studies6,12,21. 
The main adverse effects of TFA relate to plasma 
lipid concentration22. Kummerow et al. found that the 
consumption of TFAs might significantly increase LDL-c 
while reducing HDL-c levels51. A one-year follow-up of 
a cohort of 400 patients hospitalized for CVD revealed 
that a reduction of only 1% (kcal/day) in dietary TFAs 
intake was significantly associated with decreased 
LDL particle number, confirming the role of the latter 
as a confounder-independent modifiable risk factor 
and marker of disease progression52. TFAs have 
also been found to lead to greater increases in the 
plasma concentration of triglycerides than mono or 
polyunsaturated fats53. Clinical trials have suggested 
that the consumption of TFAs from hydrogenated 
vegetable oils has a negative effect on CVD due to 
their hypercholesterolemic and proinflammatory effects. 
Strong positive correlations between erythrocyte 
TFAs levels (biological marker of dietary intake) and 
markers of systemic inflammation have also been 
identified in subjects with established CVD, which 
speaks to the proinflammatory effect of TFAs intake. 
TFAs consumption is also associated with an increase 
in circulating markers of endothelial dysfunction54.
A meta-analysis of prospective studies performed 
by Mozaffarian and Rimm showed a 32% increase in 
the risk of acute myocardial infarction or CAD-related 
death for each 2% replacement of energy intake from 
carbohydrates, SFA, MFA and PUFAs, respectively, 
with TFAs41. A recent review of observational, cohort 
and randomized clinical studies21 suggested that 
animal sources have become the largest dietary 
source of TFAs after attempts by the food industry to 
reduce the use of hydrogenated fats. The effects of 
ruminant-derived TFAs on cardiovascular risk have 
not yet been fully elucidated. Some epidemiological 
studies found no association between the intake 
of ruminant-derived TFAs and the risk of coronary 
disease, while others have found positive or even 
nonsignificant negative relationships between these 
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two factors12. Data on the effects of ruminant-derived 
TFAs on plasma lipoproteins are still scarce. A study 
published by Lacroix et al.55 in the American Journal 
of Clinical Nutrition reported that the consumption of 
a butter enriched with TFAs from ruminant sources 
did not influence the concentration of LDL-c in the 
61 women who took part in the study. However, women 
with a body mass index (BMI) of at least 25 kg/m2 
showed a reduction of 2.8% in HDL-c concentration.
RECOMMENDATIONS
The DRIs (Dietary Reference Intakes) for healthy 
adults suggest that 20 to 35% of calories in the diet 
should be derived from fats56. In 200815, the World 
Health Organization (WHO) published a technical 
report with nutrient recommendations to prevent 
chronic non-communicable diseases, according 
to the guidelines established by the Food and 
Agriculture Organization of the United Nations (FAO)57. 
The recommendations for fat intake (in % of total 
calorie intake) can be found in Table 2. According to 
the V Guidelines for Dyslipidemia and the Prevention 
of Atherosclerosis issued by the Brazilian Society of 
Cardiology58, the replacement of dietary SFAs with 
n-6 PUFAs, so that the latter comprise 5 to 10% of 
total energy intake, may reduce cardiovascular risk. 
The guidelines also recommend a daily intake of 
2-4g/day of marine n-3 FAs.
The Brazilian recommendations are similar to 
those of the American College of Cardiology and 
the American Heart Association (ACC/AHA)59, which 
suggest that a daily intake of 25-30% of calories 
from fat can prevent cardiovascular risk in healthy 
individuals. The guidelines also suggest that SFAs 
should provide 5 to 6% of daily calories, while TFAs 
should make up less than 1% and cholesterol, less 
than 300mg. Additionally, the daily intake of MUFAs 
should be between 15 and 30 g and of PUFAs, between 
6 and 10%; moreover, the consumption of butters, 
hydrogenated fats, partially hydrogenated oils, as well 
as lard and palm oil, should be especially avoided59. 
In contrast, recently based on the accumulated body 
of evidence, the US Dietary Guideline suggests that 
limiting fat and cholesterol intake did not produce 
any meaningful health benefits and that increasing 
a consumption of over 35% of daily calories from 
PUFAs and MUFAs has documented health benefits60.
There is no consensus as to the maximum 
allowance of dietary TFAs. However, guidelines 
recommend that TFAs should provide no more than 
1% of total energy intake61. According to resolution 
RDC no. 360/2006 of the Brazilian National Health 
Surveillance Agency (ANVISA), the trans-fat content 
of foods should always be listed on product labels. 
However, quantities of 0.2 g or less per portion can 
be listed as “zero”62.
DIET THERAPY
Some studies suggest that Mediterranean diets 
may have beneficial effects on cardiovascular risk63-65. 
These diets are characterized by high contents 
of olive oil, fruits, nuts, vegetables, and cereals, 
moderate fish and poultry consumption, and a low 
intake of dairy products, red meats, processed meats, 
sweets, as well as moderate wine consumption66. 
A multicenter study of primary prevention in individuals 
at high risk of CVD in Spain compared the effects 
of a Mediterranean diet to those of a control diet in 
7447 participants. Cardiovascular risk decreased by 
30% in the Mediterranean diet group64. In two cohort 
studies, The Nurses’ Health Study and The Health 
Professionals Follow-up Study, the consumption 
of nuts at least seven times a week was inversely 
related to the risk of cardiovascular death in both 
men and women67.
Table 3 shows an example of a healthy Mediterranean 
diet plan developed by the authors of the present 
study, according to guidelines on PUFA intake and 
recommendations for the prevention of CVD.
FINAL CONSIDERATIONS
The nature of the relationship between FAs and 
CVD has changed as studies accumulate over 
time. The amount and types of FAs involved in the 
prevention and reduction of cardiovascular events is 
Table 3: Sample diet for the prevention of cardiovascular disease.
Breakfast 1 cup coffee with skimmed milk + 2 slices whole-wheat bread + 1 slice white cheese + 1 tablespoon 
diet jam
Morning snack 1 fruit + 3 Brazil nuts
Lunch 1 plate raw and cooked vegetables with a tablespoon of olive oil + 1 portion (120g) cooked 
salmon + 3 tablespoons brown rice + 1 ladleful beans
Afternoon snack ½ avocado mashed with lemon juice + 10 unsalted almonds + 1 skimmed yoghurt + 1 tablespoon 
ground linseed or chia
Dinner 1 plate raw and cooked vegetables with a tablespoon of olive oil + 1 portion (100g) grilled chicken
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still a matter of debate. The total amount of dietary fat 
intake does not appear to determine cardiovascular 
outcomes, so that dietary recommendations should 
focus on the types of FAs consumed. The impact of 
saturated fats on cardiovascular health appears to 
depend on their dietary source and intake. Recent 
studies have found MUFAs intake, especially in the 
form of a Mediterranean diet, to be associated with 
reductions in CVD. Dietary intake of n-3 PUFAs from 
fish plays a protective role against cardiovascular 
disease. However, supplementation with fish oil does 
not confer the same health benefits. The dietary 
replacement of saturated fats with n-6 FAs is still a 
matter of debate. There appears to be a consensus in 
the literature regarding the association between TFA 
intake and increased cardiovascular risk. As such, 
the intake of TFAs should be reduced by restricting 
the consumption of processed foods.
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